Published in Mediators Inflamm on July 18, 2012
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Dendritic cells: cellular mediators for immunological tolerance. Clin Dev Immunol (2013) 0.86
Laser vaccine adjuvants. History, progress, and potential. Hum Vaccin Immunother (2014) 0.82
Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage. J Immunol Res (2015) 0.79
Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy. Clin Dev Immunol (2013) 0.79
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. Methods Mol Biol (2016) 0.76
Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives? Transl Androl Urol (2013) 0.75
Dendritic cell immunotherapy in uterine cancer. Hum Vaccin Immunother (2014) 0.75
Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion. PLoS One (2017) 0.75
Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Taking dendritic cells into medicine. Nature (2007) 11.82
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Functions of natural killer cells. Nat Immunol (2008) 9.88
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 8.01
GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature (1992) 7.41
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol (2000) 6.04
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science (2003) 5.00
Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods (1996) 4.87
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med (2001) 4.78
CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A (1996) 4.64
Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev (2009) 4.55
T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today (1999) 4.49
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Characterization of human blood dendritic cell subsets. Blood (2002) 3.97
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity (2008) 3.94
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol (2001) 3.59
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol (2005) 3.47
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med (2010) 3.43
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol (2001) 3.41
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.20
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity (2009) 3.13
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 3.01
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med (2007) 2.98
Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol (2004) 2.87
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med (2000) 2.69
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol (2001) 2.63
Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood (2000) 2.45
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 2.37
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood (2002) 2.30
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol (1993) 2.20
Pathogen recognition by innate receptors. J Infect Chemother (2008) 2.16
High-level IL-12 production by human dendritic cells requires two signals. Int Immunol (1998) 2.15
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 1.92
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med (2001) 1.85
Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am (1999) 1.82
In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood (2000) 1.76
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 1.76
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74
Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol (2007) 1.73
Activation and inhibition of lymphocytes by costimulation. J Clin Invest (2002) 1.69
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res (2000) 1.68
Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol (2003) 1.66
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev (2003) 1.61
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol (1998) 1.52
Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol (2009) 1.49
CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol (2002) 1.47
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol (2007) 1.45
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol (2007) 1.44
Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol (1995) 1.43
T cell co-stimulatory molecules other than CD28. Curr Opin Immunol (1999) 1.43
Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J Virol (2009) 1.43
TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol (2003) 1.40
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity (2007) 1.36
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis (2005) 1.32
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med (2005) 1.31
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med (2007) 1.30
Manipulation of dendritic cell function by viruses. Curr Opin Microbiol (2010) 1.29
The instructive role of dendritic cells on T-cell responses. Arthritis Res (2002) 1.26
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol (2000) 1.23
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol (2007) 1.21
Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol (2004) 1.20
Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol (2004) 1.20
Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol (2005) 1.19
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol (2000) 1.19
mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods (2002) 1.19
Dendritic cells in cancer immunotherapy. Eur J Immunol (2010) 1.19
Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood (2005) 1.16
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Cell cycle and apoptosis. Cell Prolif (2003) 1.59
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Apoptosis: mechanisms and relevance in cancer. Ann Hematol (2005) 1.44
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol (2007) 1.44
mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther (2007) 1.40
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine (2012) 1.10
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy (2009) 1.09
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist (2012) 1.07
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. Eur J Hum Genet (2011) 1.03
Dendritic cell-based cancer gene therapy. Hum Gene Ther (2009) 1.02
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets (2004) 1.01
Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother (2006) 0.99
Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality? Autoimmun Rev (2013) 0.99
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood (2005) 0.98
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother (2009) 0.97
Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev (2012) 0.96
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 0.96
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res (2010) 0.95
Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain (2009) 0.94
Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol (2002) 0.93
Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin (2011) 0.93
Immunotherapy of acute myeloid leukemia: current approaches. Oncologist (2009) 0.92
Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy (2012) 0.91
Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol (2014) 0.90
Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. BMC Biotechnol (2007) 0.90
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS (2012) 0.88
Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. Immunol Cell Biol (2009) 0.87
Recognition of cellular implants by the brain's innate immune system. Immunol Cell Biol (2010) 0.87
Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One (2011) 0.87
Human tears reveal insights into corneal neovascularization. PLoS One (2012) 0.86
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica (2012) 0.86
Dendritic cells: cellular mediators for immunological tolerance. Clin Dev Immunol (2013) 0.86
The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. J Immunol Methods (2010) 0.85
Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother (2015) 0.85
Efficient removal of LoxP-flanked genes by electroporation of Cre-recombinase mRNA. Biochem Biophys Res Commun (2003) 0.83
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis (2004) 0.83
Highly efficient mRNA-based gene transfer in feeder-free cultured H9 human embryonic stem cells. Cloning Stem Cells (2004) 0.82
Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. Br J Haematol (2009) 0.82
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother (2013) 0.82
Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol (2007) 0.82
A novel alternative spliced chondrolectin isoform lacking the transmembrane domain is expressed during T cell maturation. J Biol Chem (2003) 0.81
Role of dendritic cells in HIV-immunotherapy. Curr HIV Res (2010) 0.81
Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother (2006) 0.80
Impact of 24 Weeks of Resistance and Endurance Exercise on Glucose Tolerance in Persons with Multiple Sclerosis. Am J Phys Med Rehabil (2015) 0.80
Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004. Blood Cells Mol Dis (2004) 0.80
Immunotherapy of hematological malignancies using dendritic cells. Bull Cancer (2008) 0.80
Extracellular nucleoside diphosphate kinase NM23/NDPK modulates normal hematopoietic differentiation. Exp Hematol (2002) 0.79
Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Mult Scler (2013) 0.79
Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology (2013) 0.79
Gene expression signatures in CD34+-progenitor-derived dendritic cells exposed to the chemical contact allergen nickel sulfate. Toxicol Appl Pharmacol (2006) 0.79
Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol (2014) 0.79
Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells. Leuk Res (2008) 0.78
Expression and localization of CHODLDeltaE/CHODLfDeltaE, the soluble isoform of chondrolectin. Cell Biol Int (2007) 0.78
Viral infections following allogeneic stem cell transplantation: how to cure the cure? Leuk Lymphoma (2010) 0.77
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. Mol Cancer (2006) 0.77
Cytokine transcript profiling in CD34+-progenitor derived dendritic cells exposed to contact allergens and irritants. Toxicol Lett (2005) 0.77
Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses. Clin Dev Immunol (2012) 0.76
Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells. Transplantation (2015) 0.75
Cell death-mediated cleavage of the attraction signal p43 in human atherosclerosis: implications for plaque destabilization. Arterioscler Thromb Vasc Biol (2010) 0.75
High Intensity Aerobic and Resistance Exercise Can Improve Glucose Tolerance in Persons With Multiple Sclerosis: A Randomized Controlled Trial. Am J Phys Med Rehabil (2016) 0.75
Capacity of CD34+ progenitor-derived dendritic cells to distinguish between sensitizers and irritants. Toxicol Lett (2005) 0.75
Electroporating Human Corneal Epithelial Cells With Interleukin 10 and Fas Ligand pDNA. Asia Pac J Ophthalmol (Phila) (2015) 0.75
Cefepime and mortality. Lancet Infect Dis (2009) 0.75
Phenotypic alterations and IL-1beta production in CD34(+) progenitor- and monocyte-derived dendritic cells after exposure to allergens: a comparative analysis. Arch Dermatol Res (2002) 0.75
Synaptopodin and 4 novel genes identified in primary sensory neurons. Mol Cell Neurosci (2005) 0.75
Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res (2003) 0.75